HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Faculty of Pharmaceutical Sciences >
Peer-reviewed Journal Articles, etc >

Possibility for Dose Optimization of Pazopanib from Its Plasma Concentration in Japanese Patients with Cancer

Files in This Item:

The file(s) associated with this item can be obtained from the following URL:

Title: Possibility for Dose Optimization of Pazopanib from Its Plasma Concentration in Japanese Patients with Cancer
Authors: Tanaka, Hiroyuki Browse this author
Hiraga, Hiroaki Browse this author
Takekuma, Yoh Browse this author →KAKEN DB
Harabayashi, Toru Browse this author
Nagamori, Satoshi Browse this author
Endo, Masayuki Browse this author
Sugawara, Mitsuru Browse this author →KAKEN DB
Keywords: pazopanib
low close
therapeutic drug monitoring
Issue Date: May-2020
Publisher: The Pharmaceutical Society of Japan (日本薬学会)
Journal Title: Biological & pharmaceutical bulletin
Volume: 43
Issue: 5
Start Page: 762
End Page: 766
Publisher DOI: 10.1248/bpb.b19-00560
PMID: 32115446
Abstract: The currently approved dose of pazopanib (800mg) is being re-examined owing to its adverse effects. The aim of this study was to evaluate the relationships among starting or maintenance doses of pazopanib, estimated pazopanib C-min, and other clinical factors, including albumin and a-1 acid glycoprotein levels, in soft-tissue sarcoma and renal cell carcinoma. We also determined whether therapeutic drug monitoring of pazopanib concentrations may be used to improve its therapeutic efficacy and prevent adverse effects. Forty patients who received pazopanib for renal cancer or soft-tissue sarcoma at the Hokkaido Cancer Center were evaluated prospectively. C-min, for pazopanib was calculated based on the measured values from the plasma samples. The efficacy and time to treatment failure were then assessed. The pazopanib maintenance doses were 200 (n=4), 400 (n=34), 600 (n=4), and 800mg (m = 1). Most patients (65%) who received a 400 mg dose had an effective pazopanib concentration (>= 20//g/mL), whereas 35% of patients who received the 400mg dose had ineffective concentrations (<20 mu g/mL). Logistic regression analysis revealed that only the albumin level was significantly associated with effective pazopanib concentrations (odds ratio: 1.37, p= 0.0234). In conclusion, a dose of 400mg had been effective and well tolerated in more than half of patients in this study. However, therapeutic drug monitoring is necessary during pazopanib therapy.
Type: article
Appears in Collections:薬学研究院 (Faculty of Pharmaceutical Sciences) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 - Hokkaido University